Samsung Biologics Strike Ruling Exposes Critical Risks in Global Biomanufacturing Supply Chains

Samsung Biologics has secured a significant legal reprieve after the Seoul High Court expanded restrictions on strike activity across nine core drug substance manufacturing processes at its Songdo campus in South Korea. The decision came ahead of a planned three-week strike scheduled to begin on October 26, 2026.

On October 20, the company's labor union postponed the strike and sought renewed negotiations with management. However, the dispute remains unresolved, leaving pharmaceutical companies and biotechnology firms with an important question: how secure is their medicine supply when a major manufacturing partner faces labor unrest?

Seoul Court Expands Restrictions Across Nine Manufacturing Stages

The Seoul High Court extended the injunction from three manufacturing stages covered by an earlier ruling in April to nine stages. These include flask culture, bioreactor culture, harvesting, media preparation and supply, chromatography, viral filtration, concentration and buffer exchange, drug substance filling, and buffer preparation and supply.

The court cited the risk of raw materials and products deteriorating if essential operations stopped. Under the ruling, the covered activities must maintain normal staffing levels, working hours, production scale, and duty of care during industrial action.

The court also imposed a potential penalty of 20 million Korean won for each violation of the injunction. The order strengthens Samsung Biologics' ability to protect critical operations, although it does not resolve the wider labor dispute.

Why Biologics Manufacturing Cannot Easily Stop

Unlike conventional chemical drug production, biologics manufacturing often relies on living cells, controlled biological conditions, and tightly coordinated processing steps. An interruption at the wrong stage can compromise a batch, increase production costs, and delay delivery.

For example, cell culture must operate under controlled conditions before the biological material moves through harvesting and purification. Chromatography and viral filtration then help process and purify the material before subsequent manufacturing steps.

A production interruption does not automatically mean every batch will be lost. The impact depends on the process stage, batch status, validated procedures, and the ability to maintain appropriate conditions. However, restarting production may require additional time, materials, quality assessments, and manufacturing capacity.

Explore our latest PDF including customized data, master dataset, company quadrant and more: https://www.towardshealthcare.com/contact-us 

Financial Exposure and Manufacturing Capacity

The financial implications are already visible. Samsung Biologics reported an estimated 150 billion Korean won impact associated with production adjustments during the five-day strike from May 1 to May 5, 2026.

Industry reporting has also put the company's combined manufacturing capacity across South Korea and the United States at approximately 845,000 litres. That scale makes operational continuity important not only for the manufacturer but also for customers relying on its facilities.

Labor Dispute Goes Beyond Salary Negotiations

The union's concerns extend beyond wages. Workers have also raised issues involving personnel policies, operational autonomy, ESG management, and employee relations.

Three rounds of mediation in September failed to resolve the disagreement. Following the court ruling, the union postponed its October 26 strike and sought to reopen discussions with management. The postponement therefore represents a change in industrial action plans, not a confirmed settlement.

For management, the challenge is to protect production while addressing employee concerns. For the union, the ruling limits its ability to disrupt essential manufacturing activities, potentially changing how it approaches future negotiations.

What Pharmaceutical Companies Should Evaluate When Selecting a CDMO

The case offers practical lessons for pharmaceutical executives, procurement leaders, supply-chain managers, and investors assessing contract manufacturing partners.

• Production concentration: Determine how much of a medicine's supply depends on one facility or manufacturing partner.

• Inventory coverage: Assess how long existing stock can support demand if a production campaign is delayed.

• Backup manufacturing: Verify whether another qualified site can manufacture the product and how much time technology transfer and regulatory approvals would require.

• Labor stability: Review employee relations, collective bargaining status, overtime restrictions, and contingency arrangements.

• Contractual protection: Check how agreements address supply interruptions, delayed deliveries, notification requirements, and responsibility for additional costs.

• Recovery planning: Establish how the manufacturer would prioritize batches, assess product quality, and restore production after an interruption.

These are recommended due-diligence questions, not confirmed weaknesses at Samsung Biologics. Their value lies in helping buyers assess operational risk before signing long-term manufacturing agreements.

Strategic Implications for the Global CDMO Industry

The Samsung Biologics dispute demonstrates that manufacturing capacity alone is not enough to establish supply reliability. Workforce stability, operational continuity, inventory management, and alternative production options also affect a CDMO's ability to meet customer commitments.

For investors, the situation highlights a distinction between installed capacity and dependable output. For pharmaceutical companies, it reinforces the need to assess business continuity alongside manufacturing cost, technical expertise, quality systems, and available capacity.

The immediate strike threat has eased, but the labor dispute remains open. The longer-term test for Samsung Biologics will be whether management and employees can reach an agreement while protecting production schedules and customer confidence.

About Us

Healthcare WebWire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium